HDAC9 and diffuse large B-cell lymphoma: Another HDAC inhibitor, mocetinostat, was tested in a phase 2 study of patients with R/R DLBCL and FL, but the drug failed to reach the threshold for clinical efficacy (> 20% ORR) [89].